EVALUATION OF THE EFFECT OF FUROSEMIDE ON ULTRAFILTERABLE PLATINUM KINETICS IN PATIENTS TREATED WITH CIS-DIAMMINEDICHLOROPLATINUM

被引:16
作者
DUMAS, M
DEGISLAIN, C
DATHIS, P
CHADOINTNOUDEAU, V
ESCOUSSE, A
GUERRIN, J
AUTISSIER, N
机构
[1] CTR LUTTE CONTRE CANC GEORGES FRANCOIS LECLER,F-21000 DIJON,FRANCE
[2] FAC PHARM DIJON,CHIM ANALYT LAB,F-21000 DIJON,FRANCE
[3] HOP BOCAGE,DEPT INFORMAT MED,F-21000 DIJON,FRANCE
关键词
D O I
10.1007/BF00258455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:37 / 40
页数:4
相关论文
共 20 条
  • [1] BELT RJ, 1979, CANCER TREAT REP, V63, P1515
  • [2] CATTERSON R, 1983, RES COMMUN CHEM PATH, V41, P255
  • [3] THE MECHANISM OF RENAL CLEARANCE OF CISPLATIN (CIS-DICHLORODIAMMINE PLATINUM-II) AND ITS MODIFICATION BY FUROSEMIDE AND PROBENECID
    DALEYYATES, PT
    MCBRIEN, DCH
    [J]. BIOCHEMICAL PHARMACOLOGY, 1982, 31 (13) : 2243 - 2246
  • [4] URINARY BETA-2-MICROGLOBULIN - EARLY INDICATOR OF HIGH-DOSE CISDIAMMINEDICHLOROPLATINUM NEPHROTOXICITY - INFLUENCE OF FUROSEMIDE
    DEGISLAIN, C
    DUMAS, M
    DATHIS, P
    LAUTISSIER, JL
    ESCOUSSE, A
    GUERRIN, J
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 18 (03) : 276 - 279
  • [5] DUMAS M, 1985, INT J CLIN PHARM TH, V23, P430
  • [6] CISPLATIN NEPHROTOXICITY - A SUMMARY OF PREVENTATIVE INTERVENTIONS
    FINLEY, RS
    FORTNER, CL
    GROVE, WR
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (05): : 362 - 367
  • [7] FRICK GA, 1979, CANCER TREAT REP, V63, P13
  • [8] GUARINO AM, 1979, CANCER TREAT REP, V63, P1475
  • [9] PHARMACOKINETICS AND PROTEIN-BINDING OF CIS-DICHLORODIAMMINE PLATINUM (II) ADMINISTERED AS A ONE-HOUR OR AS A 20-HOUR INFUSION
    GULLO, JJ
    LITTERST, CL
    MAGUIRE, PJ
    SIKIC, BI
    HOTH, DF
    WOOLLEY, PV
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1980, 5 (01) : 21 - 26
  • [10] HAYES DM, 1977, CANCER, V39, P1372, DOI 10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO